Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced
ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in …

Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …

Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not
classically “druggable,” including loss-of-function mutations in tumor suppressor genes …

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various
defective DNA repair genes; however, further studies to clinically qualify predictive …

Mutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2
deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other …